Xu, J., Yang, H., Jin, B., Lou, Y., Zhang, Y., Zhang, X., . . . Han, B. (2016). EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation. Sci Rep.
Styl ChicagoXu, Jianlin, et al. "EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-line Therapy for Non-small Cell Lung Cancer Patients With the L858R Point Mutation." Sci Rep 2016.
Citace podle MLAXu, Jianlin, et al. "EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-line Therapy for Non-small Cell Lung Cancer Patients With the L858R Point Mutation." Sci Rep 2016.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..